atients with type 1 diabetes and nephropathy carry a high risk of cardiovascular disease (1) (2) (3) . This risk cannot be fully explained by conventional risk factors. Low-grade inflammation increases the invasion of monocytes into the vascular wall, leading to the formation of atherosclerosis and cardiovascular disease (4) . The pathogenesis of vascular complications involves inflammation and endothelial dysfunction (5) (6) (7) (8) but whether biomarkers of these processes are associated with prognosis in type 1 diabetes is not known. In the Hoorn Study endothelial dysfunction and inflammation explain much of the excess risk in patients with Type 2 diabetes (9,10). In type 1 diabetic patients markers of inflammation were in a large cross-sectional study -the EURODIAB Prospective Complications Study -associated with cardiovascular disease (11) . In non-diabetic patients and in patients with type 2 diabetes longitudinal studies have demonstrated that inflammatory activity precedes vascular complications (12) . Until now no longitudinal studies have been reported in type 1 diabetic patients.
In our 10-year prospective follow-up study we tested the hypothesis that markers of inflammation and endothelial dysfunction, and TGF-β as a marker of fibrosis are associated with all-cause mortality and cardiovascular morbidity and mortality, and that markers relate to progression of diabetic nephropathy.
SUBJECTS AND METHODS
Patients and study design. In 1993, we included 199 patients with diabetic nephropathy (fulfilled clinical criteria (13) ) and 192 with persistent normoalbuminuria (urinary albumin excretion rate < 30 mg/24 h) in a prospective observational follow-up study. The inclusion criteria and selection of patients has been described previously (14) . The two groups were matched for sex, age, and duration of diabetes.
The guidelines at Steno Diabetes Center recommended statins for type 1 diabetic patient with nephropathy in 2002, and no patients were treated with statins at baseline. At baseline no patients were treated with angiotensin receptor blocker but 9 patients (5%) with normoalbuminuria and 105 (53%) were treated with angiotensin converting enzyme inhibitor. Patients were followed until December 31 2003 or until death (n = 76) or emigration (n = 3). The study was approved by the ethics committee and all patients gave informed consent. Baseline investigations. Investigations were performed after an overnight fast. No antihypertensive medication was ever prescribed in 24% of patients with nephropathy and 88% of the normoalbuminuric patients. All of the remaining patients were asked to stop their antihypertensive and diuretic treatment 8 days before the examination -however 34% and 4% of patients in the nephropathy and normoalbuminuria group, respectively, had taken antihypertensive medication at the day of the examination.
Heart rate variation (HRV) was assessed by Expiration/Inspiration (E/I) variation in heart rate (15) . The patient was, in a supine position asked to breathe deeply at the rate of 6 breaths per minute for one minute while being monitored by electrocardiogram. The maximum and minimum heart rates during each breathing cycle were measured, and the mean of the differences was calculated.
Diabetic retinopathy was assessed by fundus photography. Patients were interviewed using the WHO cardiovascular questionnaire. Smoking was defined as persons smoking one or more cigarettes/cigars/pipes a day, all others were non-smokers. Laboratory analyses. Analysis of urinary albumin concentration, serum creatinine, and GFR has been described elsewhere (14) .
GFR was measured during follow-up approximately every year. Only patients P with a minimum of three measurements was used in order to asses the rate of decline in kidney function (16) .
Analyses of the biomarkers were performed at a central lab by C.S. Highsensitivity C-reactive protein (hs-CRP) was determined by enzyme immunoassays (normal range 0.13 mg/L -3.0 mg/L) as previously described (17) . Commercially available enzyme-linked immunosorbent assay (ELISA) kits were used for measurements of plasma soluble vascular cell adhesion molecules-1 (sVCAM-1) (range for assay 538 -1286 ng/mL), soluble intercellular adhesion molecules-1 (sICAM-1) (range 98 -647 ng/mL), interleukin-6 (IL-6), secreted phospholipase A(2) (sPLA2), and plasminogen activator inhibitor-1 (PAI-1). (Quantikine High Sensitivity; R&D Systems, U.K.)). Total TGF-ß was measured by an ELISA Development system (R&D Systems). The laboratory analysis of the biomarkers was done on freezer (-80Ċ) samples. The primary endpoint was all-cause mortality and the secondary endpoint was a composite endpoint of cardiovascular death, nonfatal myocardial infarction, percutanous coronary intervention, coronary artery bypass grafting, nonfatal stroke, amputation as a result of ischemia, and vascular surgery for peripheral atherosclerotic disease (18) . Cardiovascular death was classified as all deaths for which an unequivocal noncardiovascular cause was not established (19) .
All patients alive at the follow-up examination were evaluated for endpoints in their patient file. Non-fatal events were confirmed from hospital files.
STATISTICAL ANALYSIS
At baseline, urinary albumin excretion rate, triglycerides, creatinine, and biomarkers were non-normally distributed and therefore log transformed to normal distribution and given as medians (range). All other values are means ± SD. For normally distributed variables comparison between groups was performed by unpaired Student's t-test or analysis of variance (ANOVA). A chi-square test was used to compare non-continuous variables. To combine biomarkers we constructed 2 mean Z-scores: the mean inflammatory Zscore and the mean Z-score for endothelial dysfunction biomarkers. A Z-score was calculated as: (value in individual minus the mean value in the study population) / standard deviation; the value thus ranges from approximately −2.5 to +2.5 (5). For each individual a mean Z-score was calculated combining biomarkers. The mean inflammatory Z-score = (Z-score hsCRP + Z-score IL-6 + Z-score sICAM-1 + Z-score sPLA2) / 4 and the mean Z-score for endothelial dysfunction = (Z-score PAI-1 + Z-score sVCAM-1 + Z-score sICAM-1 / 3. Since sICAM-1 is considered an inflammatory marker and a marker of endothelial dysfunction it was included in both mean Z-scores TGF-β was analyzed per se as a continuous variable. In KaplanMeier analysis groups were compared by log rank test.
A multiple Cox regression analysis (enter model) was performed with variables significantly (p<0.1) associated in a univariate analysis with all-cause mortality Prespecified were smoking, age, and sex. To avoid overfitting the model, only one parameter for kidney function, lipids, and blood pressure was used, chosen by the highest overall X 2 score. In all models the following variables used was: age, sex, systolic blood pressure, smoking, total cholesterol, HbA 1c , urinary albumin excretion, HRV, and TGF-β and either mean Z-score of inflammatory biomarkers or the mean Z-score of endothelial dysfunction biomarkers. In analysis of the specific biomarkers the 2 mean Z-scores and TGF-β were not in the model. For the "mechanistic model" age and gender was the only adjusting variables in the model, together with the specific biomarker or mean Z-score.
Progression in diabetic nephropathy was assessed as the change in GFR with time. Linear regression analysis using all measured GFR values during follow-up in each patient vs. time was used to determine the rate of decline in GFR (slope) for each patient. The correlation between rate of decline in GFR and Z-scores and log TGF-β was tested with a Pearson test for correlation.
Hazard ratios (HR) for log transformed variables are expressed as HR for a change of 1 SD in the log transformed variable. Two-tailed p values ≤ 0.05 were considered significant. All calculations were made with SPSS 12.0. Table 1 shows baseline variables. At baseline patients with diabetic nephropathy had higher IL-6, sVCAM-1, PAI-1, and TGF-β, while hsCRP, sPLA-2, and sICAM-1 did not differ between groups. IL-6, sICAM-1, sVCAM-1, and PAI-1 were higher in non-survivors at baseline (p<0.05); other biomarkers did not differ significantly between survivors and non-survivors.
RESULTS
At baseline, both mean Z-scores were correlated with known cardiovascular risk factors. Urinary albumin excretion, heart rate variation, HbA 1c , total cholesterol, and systolic blood pressure were correlated with the mean Z-score for endothelial dysfunction biomarkers and with the mean Z-score for inflammatory biomarkers (except heart rate variation); p<0.01. Age did not correlate with any of the mean Zscores. TGF-β correlated at baseline with both mean Z-scores and cholesterol (p<0.01), but not with other risk factors.
All-cause mortality. During follow-up 60 patients (30%) with nephropathy died versus 16 (8%) of normoalbuminuric patients, log rank test p<0.0001. Twentyfive patients (42%) with diabetic nephropathy died from cardiovascular causes versus 7 patients (38%) with normoalbuminuria. Thirty patients (50%) died from end stage renal disease.
When dividing patients into tertiles according to mean Z-scores we observed that patients in the lowest tertile had the lowest mortality. Fifteen, 28, and 33 patients died in the lowest, middle, and highest tertile of the mean Z-score of endothelial dysfunction; p-value for differences between the highest and lowest tertile: p=0.033. Correspondingly 18, 23, and 35 patients died in the three tertiles of the mean Z-score of inflammatory biomarkers; p=0.028. Figure 1 shows patients divided into tertiles of the mean Zscore for inflammatory biomarkers; the figure for endothelial dysfunction is not shown but is similar.
In an unadjusted Cox regression analysis, the mean Z-score for inflammatory biomarkers was significantly associated with death in all patients, but after adjusting for cardiovascular risk factors the result was no longer significant (HR 1.33 CI (0.83-2.15), p=0.241). In an analysis of patients with diabetic nephropathy per se the Z-score for low grade inflammation was significantly associated with death in unadjusted (HR 1.9 (1-3-2.8), p=0.001) and in adjusted analysis (HR 2.13 (1.17-3.88), p=0.014).
The mean Z-score for endothelial dysfunction was associated with death in all patients in unadjusted analysis and in patients with diabetic nephropathy per se, however after adjusting the association disappeared.
In a "mechanistic model" adjusting only for age and gender the results were similar to the unadjusted model, with the same biomarkers giving significant association to the outcome. The area under the receiver operating characteristic curve (AUC) for all cause mortality for all traditional risk factors used in the Cox model in all patients was 0.845. When adding Z-score for inflammation or the Z-score for endothelial dysfunction there was no change in AUC. In patients with diabetic nephropathy the AUC for all mentioned risk factors was 0.815, and in patients with normoalbuminuria 0.789. There was again no change when adding the Z-scores. TGF-β was not associated with death in the group as a whole, nor when analyzing the two groups per se. If all patients were traced in July 2007 a total of 112 patients had died. However it did not change the analysis on biomarkers substantially. Cardiovascular mortality and morbidity (table 2). During follow-up 79 patients (40%) with diabetic nephropathy reached the combined endpoint of cardiovascular death, or major cardiovascular event versus 19 patients (10%) with persistent normoalbuminuria, log rank test p<0.0001. The 79 affected patients experienced a total of 107 events.
The mean Z-score for inflammatory biomarkers was associated with the combined endpoint in all patients in unadjusted analysis (HR 1.5 (1.1-2.0), p=0.006) -after adjustment the results were borderline significant (HR 1.50 (1.0-2.25), p=0.051). In patients with diabetic nephropathy the results were significant even after adjusting for risk factors.
The mean Z-score for endothelial dysfunction was in unadjusted Cox regression analysis associated with the combined endpoint only when analyzing all patients combined (HR 1.7 (1.2-2.3), p=0.001), and the association disappeared after adjusting for cardiovascular risk factors. In a "mechanistic model" adjusting only for age and gender the results were similar to the unadjusted model.
There was no change in AUC when adding either of the Z-scores on top of risk factors used in the Cox model. TGF-β was not associated with the combined cardiovascular endpoint in the group as whole or when analyzing patients separately. Progression of renal disease. Progression of diabetic nephropathy measured as rate of decline in GFR correlated with the mean Zscore for endothelial dysfunction (r= -0.243; p=0.001), however there was no correlation between rate of decline in GFR and the mean Z-score for inflammation or TGF-β. The correlation between the mean Z-score for endothelial dysfunction and rate of decline in GFR persisted even after adjusting for urinary albumin excretion, baseline GFR, systolic blood pressure, HbA 1c , cholesterol, age, gender, and hemoglobin: Coefficient: -1.38 (95% CI -2.27, -0.50), p=0.002; meaning that per 1 unit increase in mean Z-score for endothelial dysfunction the decline in GFR increases with 1.38 ml/min/1.73 m 2 per year.
DISCUSSION
This is the first prospective study evaluating the association of biomarkers of low-grade inflammation and endothelial dysfunction with mortality and decline of GFR in type 1 diabetes. The study had three main results. First, in patients with diabetic nephropathy, low-grade inflammation (estimated from a Z-score of four markers) was associated with all-cause mortality and the combined cardiovascular endpoint after adjusting for cardiovascular risk factors. Second, in unadjusted analyses, endothelial dysfunction (estimated from a Z-score of three markers) was also associated with these endpoints. Third, endothelial dysfunction correlated significantly with the rate of decline of GFR, a measure of progression of diabetic nephropathy.
Inflammation and endothelial dysfunction are thought to be key processes in atherothrombosis (4) . Indeed, in type 2 diabetes biomarkers have already been shown in a longitudinal study to progress over time, and to precede vascular complications (12) . Our data on inflammation are in line with these concepts. The results for endothelial dysfunction were less clear but should not be interpreted to indicate that endothelial dysfunction is not involved in the development of cardiovascular disease. In fact, endothelial dysfunction was strongly correlated with cardiovascular risk factors at baseline, in agreement with previous data (11) , and to mortality outcome in unadjusted analyses. Because cardiovascular risk factors cause endothelial dysfunction, the fully adjusted model is most likely overadjusted.
Thus a reasonable interpretation is that our results are compatible with a role for endothelial dysfunction, as has been suggested before (20, 21) . Additional reasons why the association between endothelial dysfunction and mortality may have been underestimated include the fact that we were able to include only three biomarkers (data on more specific endothelial biomarkers such as sE-selectin and von Willebrand factor not being available) and that we were unable to include a more direct estimate of endothelial nitric oxide availability, e.g. by measuring flow-mediated endotheliumdependent vasodilatation (20, 22) .
We find endothelial dysfunction to correlate to progression of renal disease throughout the follow-up period indicating that endothelial dysfunction is an active part of the pathophysiology causing further progression of the glomerulosclerosis and not just in initiating disease. This is a very important and novel finding in patients with type 1 diabetes. Endothelial dysfunction has previously in patients with type 2 diabetes been shown to predict progression of renal disease (23) . Intervention studies towards endothelial dysfunction in regards to decline in kidney function must be the next step.
Our study had some limitations. First, we show results both for groups per se and in all patients together. The original design was a case-control design with intention to follow and compare the two groups. We believe that there is a significant difference in the development of endpoints, and perhaps even in the patophysiological pathway leading to disease. As a result, in the normoalbuminuric group the study may lack power to show the influence of biomarkers. Second, samples for analyses were taken at baseline only, and we therefore could not evaluate the time course of changes in biomarker levels. Third, the AUCs did not change after adding the mean Z-scores on top of traditional risk factors. Actually the AUCs were remarkably high with the traditional risk factors alone. Even though this limits the clinical value of the mean Z-scores, it does not negate the study's value with regard to providing insights into the pathophysiological role of inflammation and endothelial dysfunction. Fourth, our results on TGF-β were negative, even though, from animal models TGF-β is believed to act as a mediator of renal fibrosis (24) and antibodies against TGF-β seems to be effective as antifibrotic therapy in renal diseases at least when combined with RAS blockade (25) . However, we cannot exclude a local effect in the kidney of TGF-β. TGF-β levels were significantly higher at baseline in patients with diabetic nephropathy and perhaps most of the role of TGF-β is played before the clinical diagnosis of diabetic nephropathy is evident. Finally, we used Z-scores to estimate inflammation and endothelial function. An important assumption in the use of such Z-score is that all variables included are about equally reflective of the underlying process. On the other hand, the idea to combine biomarkers resolves some of the problem with the sometimes large biological variability of each measure (26) . Another major advantage of the mean Zscores is that is circumvents issues raised by multiple testing of single markers. Conversely, if the Z-score is not significantly related to the outcome one must be very cautious with attaching much value to other, single-marker observations.
With the new knowledge of the association of biomarkers with hard endpoints in type 1 diabetes added by our study, together with prognostic data in type 2 diabetic patients (9, 12) , and a recent post hoc analysis of the IRMA-2 trial showing irbesartan reduces inflammatory activity in patients with type 2 diabetes and microalbuminuria (27) the next step is trials with intention to alter inflammation and endothelial dysfunction as suggested in a statement by the American Heart Association (28). Patients with type 1 diabetes and nephropathy provide a group of patients in whom intervention towards inflammation and endothelial dysfunction could be targeted since we show Z-scores of inflammation and endothelial dysfunction to be associated with strong baseline risk factors, and even though the biomarkers did not add prognostic value on top of known cardiovascular risk factors they do provide insights to the pathophysiology of cardiovascular disease. 
